N/A N=16 Heat Therapy to Reduce Pain and Improve Walking Tolerance
Peripheral Arterial Disease
Primary: Peak Walking Time — 955.6; 947.7 seconds
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=25 RIXUBIS PMS India (RIXUBIS PMS)
Hemophilia B
Primary: Number of Participants With Serious Treatment-emergent Adverse Events (TEAEs) Related to RIXUBIS — 0 Participants
Phase 3 N=535 RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative
COPD (Chronic Obstructive Pulmonary Disease)
Primary: Proportion (Percentage) of Individuals Who Experience a 4 Unit Improvement in St. George's Respiratory Questionnaire (SGRQ) at 12 Weeks and do Not Meet Criteria for…
Phase 2 N=95 Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer
BRAF V600E-mutant Metastatic Colorectal Cancer
Primary: Confirmed Overall Response Rate (cORR) Based on Local Tumor Assessments — 47.8 percentage of confirmed responses
N/A N=131 Pilot Evaluation of Hospice Decision Support Tools
Hospice · End-of-life Decision Making · Hospice Decision Making
Primary: Hospice Knowledge Scale — 18; 17 score on a scale
N/A N=32 Fibrin Glue in Inguinal Lymphadenectomy
Seroma
Primary: Number of Participants With Seroma Formation — 2; 8 participants — p=0.022
N/A N=436 Study of Gelesis100 on Body Weight in Overweight and Obese Subjects With and Without Type 2 Diabetes
Overweight · Obesity
Primary: Co-Primary Outcome: Percent Change in Body Weight — -6.41; -4.39 percentage change in body weight — p=0.0007
Phase 2 N=360 A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease
Alzheimer Disease (AD)
Primary: Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) — -13.72; -15.11; -14.38 score on a scale
Phase 2 N=58 Oxytocin on Irritability/Emotional Dysregulation of Disruptive Behavior and Mood Disorders
Mood Disorder · Disruptive Behavior Disorders
Primary: Change in Affective Reactivity Index - Youth (ARI-Y) — -2.9; -0.8 score on a scale
Phase 2 N=132 Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection
Clostridium Difficile Infection · Recurrent Clostridium Difficile Infection · C. Diff
Primary: Number of Participants With Absence of Recurrence Through Week 8 Based on Adjudication — 106 Participants
N/A N=65 MiniMed™ 670G System China Study for Type I Diabetic
Diabetes Mellitus, Type 1
Primary: Change in Time in Target Range (% of Sensor Glucose (SG)): 70 mg/dL (3.9 mmol/L) ≤ SG ≤ 180 mg/dL (10 mmol/L) — 75.3; 80.9; 5.6 percentage of total readings — p=<0.001
N/A N=144 Underutilization of Hospice in Older African Americans
Hospice Decision Making
Primary: Hospice Knowledge Scale — 17; 17 units on a scale
Phase 2 N=28 Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma
Metastatic Myxoid Liposarcoma · Metastatic Round Cell Liposarcoma · Metastatic Synovial Sarcoma
Primary: Overall Response Rate (ORR) — 6; 0 Participants
Phase 4 N=17 The Use of Medical Grade Honey in the Prevention of Bone Anchored Hearing Aid Associated Skin Breakdown
Skin Infection
Primary: Holgers Classification of Skin Reactions at the Surgical Site Graded 0 (no Reaction) to 4 (Worse Outcome) — 1.06; 0.64; 0.81; 0.50 Grade
Phase 3 N=424 Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)
Atopic Dermatitis
Primary: Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16 — 12.7; 43.1 percentage of…